 Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd NYSE: CANF said that the topline data from its Phase 3 Comfort study of Piclidenoson in severe plaque psoriasis would be released in Q2 2022. Earlier, the data were anticipated in Q1 of 2022. 